Association between type 2 diabetes mellitus and prostate cancer

References

[1] Grossmann M.Androgens, diabetes and prostate cancer.Endocr Relat Cancer2012;19:F47-62

[2] Tsilidis KK,Appleby PN.Diabetes mellitus and risk of prostate cancer in the European prospective investigation into cancer and nutrition.Int J Cancer2015;136:372-81

[3] Zaccardi F,Yates T.Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective.Postgrad Med J2016;92:63-9

[4] Beckmann K,Nelson WG.Hormonal patterns in men with prediabetes and diabetes in NHANES III: possible links with prostate cancer.Cancer Causes Control2022;33:429-40 PMCID:PMC9066414

[5] Giovannucci E,Archer MC.Diabetes and cancer: a consensus report.Diabetes Care2010;33:1674-85 PMCID:PMC2890380

[6] Bansal D,Kapil G,Tiwari P.Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies.Prostate Cancer Prostatic Dis2013;16:151-8, S1

[7] Darbinian JA,Van Den Eeden SK,Fireman B.Glycemic status and risk of prostate cancer.Cancer Epidemiol Biomarkers Prev2008;17:628-35

[8] Lavalette C,Rébillard X.Diabetes, metabolic syndrome and prostate cancer risk: results from the EPICAP case-control study.Cancer Epidemiol2022;81:102281

[9] Lin E,Van Hemelrijck M.Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study.BMC Cancer2020;20:551 PMCID:PMC7294669

[10] Fall K,Gudbjörnsdottir S,Zethelius B.Diabetes mellitus and prostate cancer risk; a nationwide case-control study within PCBaSe Sweden.Cancer Epidemiol Biomarkers Prev2013;22:1102-9

[11] Turner EL,Donovan JL.Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study).Int J Cancer2011;128:440-6

[12] Smith MR,Efstathiou JA.Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02.J Clin Oncol2008;26:4333-9 PMCID:PMC2653118

[13] Murtola TJ,Lahtela J.Fasting blood glucose, glycaemic control and prostate cancer risk in the finnish randomized study of screening for prostate cancer.Br J Cancer2018;118:1248-54 PMCID:PMC5943324

[14] Ma C,Han B.Poorly controlled diabetes mellitus increases the risk of deaths and castration-resistance in locally advanced prostate cancer patients.Cancer Invest2023;41:345-53

[15] Onitilo AA,Berg RL.Type 2 diabetes mellitus, glycemic control, and cancer risk.Eur J Cancer Prev2014;23:134-40.

[16] Jayedi A,Rezagholizadeh F,Hajimohammadi M.Fasting blood glucose and risk of prostate cancer: a systematic review and meta-analysis of dose-response.Diabetes Metab2018;44:320-7

[17] Monroy-Iglesias MJ,Crawley D.Metabolic syndrome biomarkers and prostate cancer risk in the UK Biobank.Int J Cancer2021;148:825-34.

[18] Hitron A,Talbert J.The influence of antidiabetic medications on the development and progression of prostate cancer.Cancer Epidemiol2012;36:e243-50

[19] Gang P, Mo L, Lu Y, Runqi L, Xing Z. Diabetes mellitus and the risk of prostate cancer: an update and cumulative meta-analysis.Endocr Res2015;40:54-61.

[20] Ahearn TU,Pettersson A.Transdisciplinary prostate cancer partnership (ToPCaP)Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease.Carcinogenesis2018;39:1431-7 PMCID:PMC6314328

[21] Travis RC,Martin RM.A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk.Cancer Res2016;76:2288-300

[22] King ER.Insulin-like growth factor: current concepts and new developments in cancer therapy.Recent Pat Anticancer Drug Discov2012;7:14-30. PMCID:PMC3724215

[23] Heni M,Scharpf M.Insulin receptor isoforms A and B as well as insulin receptor substrates-1 and -2 are differentially expressed in prostate cancer.PLoS One2012;7:e50953 PMCID:PMC3519512

[24] Watts EL,Smith Byrne K.Circulating insulin-like growth factor-I, total and free testosterone concentrations and prostate cancer risk in 200 000 men in UK Biobank.Int J Cancer2021;148:2274-88 PMCID:PMC8048461

[25] Hosseini L,Kharazi U.The Association of type 2 diabetes and site-specific cancers: linking mechanisms.Crit Rev Oncog2019;24:259-67.

[26] Lutz SZ,Scharpf MO.Androgen receptor overexpression in prostate cancer in type 2 diabetes.Mol Metab2018;8:158-66 PMCID:PMC5985051

[27] Yassin A,Alzubaidi R,Al Ansari A.Testosterone, testosterone therapy and prostate cancer.Aging Male2019;22:219-27

[28] Kaplan AL,Morgentaler A,Schulman CC.Testosterone therapy in men with prostate cancer.Eur Urol2016;69:894-903 PMCID:PMC5000551

[29] Gong Z,Goodman PJ.Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial.Cancer Epidemiol Biomarkers Prev2006;15:1977-83

[30] Khan S,Nielsen ME.The association of diabetes and obesity with prostate cancer progression: HCaP-NC.Prostate2017;77:878-87 PMCID:PMC5695861

[31] Choi JB,Park YH.The impact of diabetes on the risk of prostate cancer development according to body mass index: a 10-year nationwide cohort study.J Cancer2016;7:2061-6 PMCID:PMC5118669

[32] Lee IM,Paffenbarger RS Jr.A prospective cohort study of physical activity and body size in relation to prostate cancer risk (United States).Cancer Causes Control2001;12:187-93

[33] Wright ME,Schatzkin A.Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality.Cancer2007;109:675-84.

[34] Suarez Arbelaez MC,Shah K.Association between body mass index, metabolic syndrome and common urologic conditions: a cross-sectional study using a large multi-institutional database from the United States.Ann Med2023;55:2197293 PMCID:PMC10088970

[35] Barrington WE,Etzioni R.Difference in association of obesity with prostate cancer risk between US african american and non-hispanic white men in the selenium and Vitamin E cancer prevention trial (SELECT).JAMA Oncol2015;1:342-9. PMCID:PMC4570268

[36] Zhu D,Shyr W,Watts KL.Association of obesity and diabetes with prostate cancer risk groups in a multiethnic population.Clin Genitourin Cancer2022;20:299.e10

[37] Francesco S, Tenaglia RL. Obesity, diabetes and aggressive prostate cancer hormone-naïve at initial diagnosis.Cent European J Urol2014;66:423-7. PMCID:PMC3992450

[38] Bub JD,Iwamoto Y.Adiponectin as a growth inhibitor in prostate cancer cells.Biochem Biophys Res Commun2006;340:1158-66

[39] Burton A,Holly J.Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study.Cancer Causes Control2013;24:323-34

[40] Lonardo A,Targher G.Precision medicine approaches in metabolic disorders and target organ damage: where are we now, and where are we going?.Metab Target Organ Damage2021;1:3

[41] Tayanloo-Beik A,Payab M.OMICS insights into cancer histology; Metabolomics and proteomics approach.Clin Biochem2020;84:13-20.

[42] Genchi VA,Colzani M.New antidiabetic drugs’ role in the management of testosterone deficiency and of the cardiovascular disease in hypogonadal diabetic men.Metab Target Organ Damage2023;3:8